Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases
dc.contributor.author | Crofford, Leslie J. | en_US |
dc.contributor.author | Oates, James C. | en_US |
dc.contributor.author | McCune, William Joseph | en_US |
dc.contributor.author | Gupta, Samardeep | en_US |
dc.contributor.author | Kaplan, Mariana J. | en_US |
dc.contributor.author | Catella-Lawson, Francesca | en_US |
dc.contributor.author | Morrow, Jason D. | en_US |
dc.contributor.author | McDonagh, Kevin T. | en_US |
dc.contributor.author | Schmaier, Alvin H. | en_US |
dc.date.accessioned | 2006-04-19T13:27:11Z | |
dc.date.available | 2006-04-19T13:27:11Z | |
dc.date.issued | 2000-08 | en_US |
dc.identifier.citation | Crofford, Leslie J.; Oates, Jim C.; McCune, W. Joseph; Gupta, Samardeep; Kaplan, Mariana J.; Catella-Lawson, Francesca; Morrow, Jason D.; McDonagh, Kevin T.; Schmaier, Alvin H. (2000)."Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases." Arthritis & Rheumatism 43(8): 1891-1896. <http://hdl.handle.net/2027.42/34296> | en_US |
dc.identifier.issn | 0004-3591 | en_US |
dc.identifier.issn | 1529-0131 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/34296 | |
dc.identifier.uri | http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=10943882&dopt=citation | en_US |
dc.description.abstract | Specific inhibitors of cyclooxygenase 2 (COX-2) have been approved for the treatment of osteoarthritis and rheumatoid arthritis. Unlike nonsteroidal anti-inflammatory drugs, specific COX-2 inhibitors do not inhibit platelet activation. However, these agents significantly reduce systemic production of prostacyclin. As a result, theoretical concerns have been raised that specific COX-2 inhibitors could shift the hemostatic balance toward a prothrombotic state. Patients with connective tissue diseases (CTD), who may be predisposed to vasculopathy and thrombosis, often have arthritis or pain syndromes requiring treatment with antiinflammatory agents. Herein we describe 4 patients with CTD who developed ischemic complications after receiving celecoxib. All patients had a history of Raynaud's phenomenon, as well as elevated anticardiolipin antibodies, lupus anticoagulant, or a history compatible with antiphospholipid syndrome. It was possible to measure a urinary metabolite of thromboxane A 2 in 2 of the patients as an indicator of in vivo platelet activation, and this was markedly elevated in both. In addition, the patients had evidence of ongoing inflammation as indicated by elevated erythrocyte sedimentation rate, hypocomplementemia, and/or elevated levels of anti-DNA antibodies. The findings in these 4 patients suggest that COX-2 inhibitor–treated patients with diseases that predispose to thrombosis should be monitored carefully for this complication. | en_US |
dc.format.extent | 528735 bytes | |
dc.format.extent | 3118 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.language.iso | en_US | |
dc.publisher | John Wiley & Sons, Inc. | en_US |
dc.subject.other | Life and Medical Sciences | en_US |
dc.title | Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Geriatrics | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor ; 5510E MSRB I, 1150 West Medical Center Drive, Ann Arbor, MI 48109-0680 | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor | en_US |
dc.contributor.affiliationum | University of Michigan, Ann Arbor | en_US |
dc.contributor.affiliationother | Medical University of South Carolina, Charleston | en_US |
dc.contributor.affiliationother | University of Pennsylvania, Philadelphia | en_US |
dc.contributor.affiliationother | Vanderbilt University, Nashville, Tennessee | en_US |
dc.identifier.pmid | 10943882 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/34296/1/28_ftp.pdf | en_US |
dc.identifier.doi | http://dx.doi.org/10.1002/1529-0131(200008)43:8<1891::AID-ANR28>3.0.CO;2-R | en_US |
dc.identifier.source | Arthritis & Rheumatism | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.